Nurix enrolls first patient in bexobrutideg combination CLL study
Tweet Send to a Friend
Nurix Therapeutics, Inc. (Nasdaq: NRIX) announced that the first patient has been enrolled in its Phase 1b/2 NX-5948-203 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




